Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix

Human Reproduction

Volumn 16, Issue 4, 2001, Pages 663-667

  Tavaniotou, Asimina ^a   Albano, Carola ^a   Smitz, Johan ^a   Devroey, Paul ^a  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

GnRH antagonist; IVF; LH; Luteal phase; Ovarian stimulation

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE; UROFOLLITROPIN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INJECTION; LUTEAL INSUFFICIENCY; LUTEAL PHASE; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MENSTRUAL CYCLE; NEGATIVE FEEDBACK; OVULATION INDUCTION; PREGNANCY; RETROSPECTIVE STUDY;

EID: 0035067872     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.4.663     Document Type: Article

References (36)

1. Hormonal profile during the follicular phase in cycles stimulated with a combination of human gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix)
2. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation
3. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelex
4. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles
5. Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor
6. Progesterone stimulates luteinizing hormone secretion by acting directly on the pituitary
7. The control of gonadotrophin secretion by ovarian steroids
8. Disapperance of exogenously administered human chorionic gonadotropin
9. Control of LH secretion: Role of a 'short' feedback mechanism
10. Variations of luteinizing hormone serum concentrations after exogenous human chorionic gonadotropin administration during ovarian hyperstimulation
11. A randomized, assessor-blind, group comparative efficacy study to compare to effects of Normegon® and Metrodin® in infertile female patients undergoing in-vitro fertilization
12. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
13. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility
14. Hormone profiles under ovarian stimulation with uman menopausal gonadotropin (HMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages
15. A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: Controlled restoration of gonadotropin secretion and ovulation induction
16. Inability to demonstrate an ultrashort loop feedback mechanism for luteinizing hormone in humans
17. Novel presence of luteinizing hormone/human chorionic gonadtropin (HCG) receptors gene and the down-regulating action of HCG on gonadotropin-releasing hormone gene expression in immortalized hypothalamic GT1-7 neurons
18. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: Further evidence for the role of GnRH during the LH surge
19. Human chorionic gonadotropin down-regulates the expression of gonadotropin-releasing hormone receptor gene in GT1-7 neurons
20. A randomized three-way cross over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration
21. The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe
22. Disparate effects of endogenous and exogenous oestradiol on luteal phase function in women
23. Activation of LH receptors expressed in GnRH stimulates cyclic AMP production and inhibits pulsatile neuropeptidase release
24. The time course change after castration in short-loop negative control of LH by HCG in women
25. Suppression of serum levels of luteinizing hormone by short- and long-loop negative feedback in ovariectomized women
26. Endogenous luteinizing hormone surges following administration of human chorionic gonadotropin: Further evidence for lack of loop feedback in humans
27. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle
28. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pre-treated with a GnRH antagonist
29. Prevention of the postcoital luteinizing hormone surge by ultrashort feedback control
30. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-realsing analogue (nafarelin)
31. Human chorionic gonadotropin blocks the estrogen-induced luteinizing hormone release in long-term castrated monkeys: Evidence for an ultrashort-loop negative feedback
32. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for supervolution in IVF or GIFT
33. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol
34. Role of endogenous opioids in reducing the frequency of pulsatile luteinizing hormone secretion induced by progesterone in normal women
35. Positive and negative feed-back effect of progesterone on luteinizing hormone secretion in post-menopausal women
36. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women